Latest Safety News

Page 83 of 146
Alterity Therapeutics has secured U.S. FDA Fast Track designation for its drug ATH434 targeting Multiple System Atrophy, supported by promising Phase 2 clinical trial data showing slowed disease progression and a solid safety profile.
Ada Torres
Ada Torres
30 July 2025
Tanami Gold NL reported significant drilling progress at its Central Tanami Project with promising gold intercepts at Jims Gold Mine, while Mount Gibson Iron moves to acquire a 50% stake in the joint venture.
Maxwell Dee
Maxwell Dee
30 July 2025
Element 25 Limited has locked in AU$50 million in senior debt from the Northern Australia Infrastructure Facility to expand its Butcherbird manganese project, while advancing its US battery-grade manganese refinery with significant government grants and patent protections.
Maxwell Dee
Maxwell Dee
30 July 2025
Syrah Resources has resumed production at its Balama graphite mine after a year-long halt and is advancing sales at its US Vidalia anode material facility, supported by new US tariffs on Chinese imports and a $70 million equity raise.
Maxwell Dee
Maxwell Dee
30 July 2025
Syntara Limited reports encouraging Phase 2 data for its lead drug amsulostat in myelofibrosis, secures FDA Fast Track status, and expands clinical programs into myelodysplastic syndrome and keloid scars.
Ada Torres
Ada Torres
30 July 2025
Cynata Therapeutics is advancing three pivotal clinical trials targeting acute Graft versus Host Disease, osteoarthritis, and kidney transplantation, with major results expected through early 2026. The company maintains a solid cash position supporting its clinical pipeline and strategic growth.
Ada Torres
Ada Torres
30 July 2025
Prescient Therapeutics has secured FDA Fast Track designation for PTX-100 in treating relapsed Cutaneous T-Cell Lymphoma and dosed the first patient in its Phase 2a trial, supported by a recent $6.8 million capital raise.
Ada Torres
Ada Torres
30 July 2025
Aurora Labs has advanced its micro gas turbine program with key test bench upgrades, a significant Defence grant, and strategic partnerships, positioning itself for international defence market entry.
Victor Sage
Victor Sage
30 July 2025
Core Lithium has repositioned its Finniss Lithium Project as a low-cost underground operation with a 20-year mine life, slashing operating costs by a third and boosting production capacity. The company is advancing strategic funding while unlocking flexibility through a key offtake agreement termination.
Maxwell Dee
Maxwell Dee
30 July 2025
Neurizon Therapeutics has made significant strides in developing its lead ALS drug candidate NUZ-001, unveiling a new liquid formulation and submitting a key regulatory response to the FDA. Clinical and preclinical data bolster hopes for broader neurodegenerative applications.
Ada Torres
Ada Torres
30 July 2025
dorsaVi has acquired exclusive global rights to advanced RRAM technology, promising major performance gains in its biomedical sensors, while securing key contracts and raising $2.44 million to fuel US market growth.
Victor Sage
Victor Sage
30 July 2025
Actinogen Medical has reached a key milestone in its XanaMIA phase 2b/3 Alzheimer’s trial with over 100 participants enrolled, setting the stage for an interim analysis in January 2026. The company also secured a $13.8 million non-dilutive R&D funding facility to support ongoing development.
Ada Torres
Ada Torres
30 July 2025